Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Autor:
Marijke Stigter-van Walsum, Gerd Stehle, Heiko G. Niessen, Egbert F. Smit, Paul Slobbe, Flavio Solca, Albert D. Windhorst, Guus A.M.S. van Dongen, Alex J. Poot
Publikováno v:
EJNMMI Research
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Background Tyrosine kinase inhibitors (TKIs) have experienced a tremendous boost in the last decade, where more than 15 small molecule TKIs have been approved by the FDA. Unfortunately, despite their promising clinical successes, a large portion of p
Autor:
Sebastian Eigner, Katerina Eigner Henke, Frantisek Melichar, René Leyva Montaña, Milos Beran, Denis R. Beckford Vera
Publikováno v:
Recent Results in Cancer Research ISBN: 9783642279935
The epidermal growth factor receptor (EGFR) is a rational target of anticancer therapies due to its overexpression in a variety of malignant epithelial tumors. Nevertheless, this antigen is also present in normal tissues. Consequently, monoclonal ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f60879eccc3d801627b44b0cfab5b83b
https://doi.org/10.1007/978-3-642-27994-2_16
https://doi.org/10.1007/978-3-642-27994-2_16
Publikováno v:
Therapeutic Kinase Inhibitors ISBN: 9783642282959
Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16508bc101ff839b15db7d8d2ec4390d
https://doi.org/10.1007/82_2011_178
https://doi.org/10.1007/82_2011_178
Autor:
William Pao, Yixuan Gong
Publikováno v:
Therapeutic Kinase Inhibitors ISBN: 9783642282959
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b9c5da8c1f39c56500b90581dbffcb6
https://doi.org/10.1007/82_2011_171
https://doi.org/10.1007/82_2011_171
Autor:
Rafal Piestrzeniewicz, Miroslawa Z. Barciszewska, Monika Nowak, Stanisław Nowak, Eliza Wyszko, Jan Barciszewski, Katarzyna Rolle, Zukiel R, Iwona Gawronska
Publikováno v:
Therapeutic Ribonucleic Acids in Brain Tumors ISBN: 9783642004742
Malignant gliomas preferentially express a number of surface markers that may be exploited as therapeutic targets, such as tenascin-C, an extracellular matrix glycoprotein which contributes to tumor cell adhesion, invasion, migration, and proliferati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f29bfa3a2c17ea6e277a8904db2ed1e
https://doi.org/10.1007/978-3-642-00475-9_11
https://doi.org/10.1007/978-3-642-00475-9_11
Autor:
A Jakobovits
Publikováno v:
Therapeutic Antibodies ISBN: 9783540732587
Early detection of prostate cancer (PCa) and advances in hormonal and chemotherapy treatments have provided great clinical benefits to patients with early stages of the disease. However, a significant proportion of patients still progress to advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d776c88def44e13080465fa21313f1a2
https://doi.org/10.1007/978-3-540-73259-4_11
https://doi.org/10.1007/978-3-540-73259-4_11
Autor:
Anderson J. Ryan, Alan Barge
Publikováno v:
Tumor Angiogenesis ISBN: 9783540331766
Vandetanib ( ZACTIMA™; ZD6474) is a once-daily, orally available agent with potential for use in a number of solid tumour types. Vandetanib targets key signalling pathways in cancer by inhibiting vascular endothelial growth factor receptor (VEGFR)-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7de834d6afb2221a87b65bd6f0c52de7
https://doi.org/10.1007/978-3-540-33177-3_41
https://doi.org/10.1007/978-3-540-33177-3_41
Publikováno v:
Current Topics in Microbiology and Immunology ISBN: 9783642800733
Cancer therapy is entering a critical period. Conventional approaches for cancer treatment, such as chemotherapy, radiotherapy, or surgery, have obtained results only in lymphoproliferative neoplasms and in a small percentage of solid tumors. The cau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7044c6f9fa0f8dd65c1ead0901c28c7
https://doi.org/10.1007/978-3-642-80071-9_11
https://doi.org/10.1007/978-3-642-80071-9_11